Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
Clearside Biomedical, Inc. (CLSD) is a biopharmaceutical company that focuses on delivering therapies to the back of the eye through the suprachoroidal space (SCS®). News about CLSD frequently centers on its patented SCS injection platform, its commercial product XIPERE® for uveitic macular edema, and its lead development program CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD).
Investors and observers following CLSD news can expect updates on clinical data from Phase 1/2a and Phase 2b trials of CLS-AX, regulatory interactions such as End-of-Phase 2 meetings and Phase 3 program planning, and preclinical work on small molecule programs targeting geographic atrophy and diabetic macular edema. Company announcements also highlight scientific presentations at major ophthalmology meetings, including ARVO, EURETINA, and other retinal-focused conferences, where Clearside and its collaborators discuss suprachoroidal delivery, trial designs, and platform-related technologies.
Clearside’s news flow also includes developments from its licensing and collaboration partners. These items may cover regulatory approvals and filings for XIPERE or ARCATUS® in various territories, progress in partner-led clinical programs using the SCS Microinjector, and updates on gene therapy or anti-tumor agents delivered via the suprachoroidal route. Corporate and financial updates, such as quarterly results, strategic review announcements, reverse stock split actions, royalty monetization agreements, and Nasdaq listing compliance matters, are also part of the company’s regular disclosures.
More recently, CLSD news has included its decision to explore strategic alternatives for its SCS platform and pipeline, and the subsequent voluntary Chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware with the stated objective of pursuing a sale of substantially all assets. For users tracking CLSD, this news page provides a centralized view of clinical, regulatory, partnership, and restructuring developments affecting the company and its stock.
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced multiple presentations at the ARVO 2022 Annual Meeting showcasing its suprachoroidal delivery platform, XIPERE®, and SCS Microinjector®. Key findings indicated that the SCS Microinjector allowed targeted and durable delivery of small molecule suspensions, demonstrating potential for improved retinal therapies. XIPERE, approved by the FDA in 2021, is now commercially available for treating macular edema associated with uveitis. Dr. Thomas Ciulla will also participate in the Retina World Congress 2022 for further discussions on retinal diseases.
Clearside Biomedical (NASDAQ: CLSD) will report its Q1 2022 financial results on May 11, 2022, post-market close. Following the announcement, management will host a webcast at 4:30 p.m. ET for discussion and corporate updates. Clearside Biomedical focuses on delivering therapies to the back of the eye via its proprietary SCS Microinjector, aiming to enhance vision in patients with sight-threatening conditions. The company’s product, XIPERE, is already available in the U.S.
Clearside Biomedical (Nasdaq: CLSD) announced that its Chief Medical Officer, Thomas A. Ciulla, will present at the Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation will highlight Clearside's innovative approach to delivering therapies to the back of the eye through the suprachoroidal space (SCS).
For those interested, a live and archived webcast will be accessible on the Clearside website under the Investors section.
Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.
Clearside Biomedical (NASDAQ:CLSD) reported a significant milestone of $20 million in non-dilutive funding in Q4 2021, primarily from XIPERE commercialization partners. The company's license revenue for Q4 2021 soared to $25.7 million compared to just $11,000 in Q4 2020. A net income of $18.7 million was achieved, reflecting a marked improvement over the prior year's loss. The ongoing Phase 1/2a OASIS trial of CLS-AX for wet AMD is progressing, with results from Cohort 3 anticipated mid-2022 and a new Cohort 4 planned. Management will provide updates through a conference call today.
Clearside Biomedical has appointed Dr. Benjamin R. Yerxa to its Board of Directors, effective March 2, 2022. Dr. Yerxa, CEO of the Foundation Fighting Blindness, brings over 25 years of experience in ophthalmology and biotechnology. His insight will support the advancement of CLS-AX, a treatment targeting wet age-related macular degeneration. The company continues to develop its proprietary SCS injection platform, which enables targeted therapy delivery to the eye. Clearside aims to play a vital role in treating sight-threatening diseases amidst a growing need in the healthcare sector.
ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, a biopharmaceutical company, announced its participation in two investor conferences in March 2022. The company will present at the 42nd Annual Cowen Health Care Conference on March 8 at 9:50 am ET and the 34th Annual ROTH Conference from March 14-15 in Dana Point, CA. Investors can access live and archived webcasts on the Clearside website. The company focuses on innovative therapies delivered to the back of the eye via its proprietary SCS Microinjector.
Clearside Biomedical (NASDAQ:CLSD) will report its fourth quarter and full year 2021 financial results on March 10, 2022, post-market. A conference call and webcast will follow at 4:30 PM ET for discussion and corporate updates. Clearside is known for its innovative suprachoroidal space (SCS) technology that enhances therapy delivery to the eye. Their first product, XIPERE™, was FDA-approved in October 2021, marking a significant advancement in vision-preserving treatments.
Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations on its suprachoroidal injection platform at the Bascom Palmer Eye Institute event held on February 11-12, 2022. The presentations highlighted the advantages of using the SCS Microinjector for targeted delivery of therapies to the retina. Preclinical studies suggest superior performance compared to traditional methods. Additionally, REGENXBIO shared positive interim data from its Phase 2 trial of RGX-314 for diabetic retinopathy, showing significant patient improvement with no serious adverse effects.
Clearside Biomedical (Nasdaq: CLSD) announced its suprachoroidal space (SCS) injection platform will be featured at key medical events in February 2022. This includes oral presentations at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration Virtual Event, where updates on gene therapy RGX-314 will also be shared. Additionally, Clearside will participate in the Raymond James Preview event discussing novel injectable approaches for anti-VEGF therapy. The SCS Microinjector is highlighted for its potential to improve targeted delivery of treatments for retinal diseases.